It is made available under a CC-BY-ND 4.0 International license .

1 Research article

2

- 3 Dry loop-mediated isothermal amplification assay for detection of SARS-CoV-2 from
- 4 clinical specimens
- 5
- 6 Yuki Higashimoto^{1*}, Masaru Ihira², Yoshiki Kawamura³, Masato Inaba⁴, Kazuya Shirato⁵,
- 7 Tadaki Suzuki⁶, Hideki Hasegawa⁷, Tsutomu Kageyama⁷, Yohei Doi⁴, Tadayoshi Hata⁸, and

8 Tetsushi Yoshikawa³

- 9
- ¹ Faculty of Medical Technology, Fujita Health University School of Health Sciences,
 Toyoake, Aichi, Japan
- ² Faculty of Clinical Engineering, Fujita Health University School of Health Sciences,
- 13 Toyoake, Aichi, Japan
- ³ Department of Pediatrics, Fujita Health University School of Medicine, Toyoake, Aichi,
- 15 Japan
- ⁴ Department of Infectious Diseases, Fujita Health University School of Medicine, Toyoake,
- 17 Aichi, Japan
- ⁵ Department of Virology III, National Institute of Infectious Diseases, Musashimurayama,
- 19 Tokyo, Japan
- ⁶ Department of Pathology, National Institute of Infectious Diseases, Musashimurayama,

It is made available under a CC-BY-ND 4.0 International license .

- 21 Tokyo, Japan
- 22⁷ Influenza Virus Research Center, National Institute of Infectious Diseases,
- 23 Musashimurayama, Tokyo, Japan
- ⁸ Department of Clinical Laboratory, Fujita Health University Hospital, Toyoake, Japan

25

- 27 * Corresponding Author
- 28 E-mail: yhigashi@fujita-hu.ac.jp (YH)

It is made available under a CC-BY-ND 4.0 International license .

29 Abstract

30 Coronavirus disease 2019 (COVID-19) has had a major disease burden on many countries around 31the world. The spread of COVID-19 is anticipated to have a major impact on developing countries 32including African nations. To establish a point-of-care test for COVID-19, we developed a dry loop-mediated isothermal amplification (LAMP) method to detect severe acute respiratory 33 syndrome coronavirus 2 (SARS-CoV-2) RNA. We carried out reverse transcription (RT)-LAMP 3435using the Loopamp SARS-CoV-2 Detection kit (Eiken Chemical, Tokyo, Japan). The entire mixture except for the primers is dried and immobilized inside the tube lid. To determine the specificity of 36 the kit, 22 viral genomes associated with respiratory infections, including the SARS coronavirus, 3738 were tested. No LAMP product was detected in reactions performed with RNA from these 39 pathogens. The sensitivity of this assay, determined by either a real-time turbidity assay or 40 colorimetric change of the reaction mixture, as evaluated by the naked eye or under illumination with ultraviolet light, was 10 copies/reaction. After the initial validation analysis, we analyzed 24 41nasopharyngeal swab specimens collected from patients suspected to have COVID-19. Nineteen 42(79.2%) of the 24 samples were positive for SARS-CoV-2 RNA, as determined by real-time 4344RT-PCR analysis. Using the Loopamp SARS-CoV-2 Detection kit, we detected SARS-CoV-2 RNA 45in 15 (62.5%) of the 24 samples. Thus, the sensitivity, specificity, positive predictive value, and negative predictive value of the Loopamp 2019-CoV-2 detection reagent kit were 94.0%, 96.0%, 46 4795.9%, and 94.1%, respectively. The dry LAMP method for detection of SARS-CoV-2 RNA was 48fast and easy to use, solves the cold chain problem, and therefore represents a promising tool for

It is made available under a CC-BY-ND 4.0 International license .

49 diagnosis of COVID-19 in developing countries.

It is made available under a CC-BY-ND 4.0 International license .

51 Author summary

52	Coronavirus disease 2019 (COVID-19) is a major public health problem around the world. A
53	reliable point-of-care (POC) test for severe acute respiratory syndrome coronavirus 2 (SARS
54	CoV-2) is urgently needed, especially in developing countries. The loop-mediated isothermal
55	amplification (LAMP) method amplifies template nucleotides under isothermal conditions with
56	high efficiency and specificity, both of which are major advantages for a POC test. In addition,
57	because dry LAMP reagents can be stored at 4°C, it is suitable for use in developing countries.
58	We evaluated the specificity and sensitivity of the Loopamp SARS-CoV-2 Detection kit (Eiken
59	Chemical, Tokyo, Japan), a dry LAMP method for amplifying viral RNA. The initial validation
60	study revealed that the method was highly specific and sensitive (lower detection limit: 10
61	copies/reaction). We then analyzed 24 nasopharyngeal swab specimens from patients suspected to
62	have COVID-19. Using the Loopamp SARS-CoV-2 Detection kit, SARS-CoV-2 RNA was detected
63	in 15 (62.5%) of the 24 samples. Compared with the standard real-time reverse transcription PCR,
64	the sensitivity, specificity, positive predictive value, and negative predictive value of the Loopamp
65	SARS-CoV-2 Detection kit were 78.9%, 100%, 100%, and 55.6%, respectively.

It is made available under a CC-BY-ND 4.0 International license .

67 Introduction

69	The outbreak of coronavirus disease 2019 (COVID-19), caused by the novel coronavirus designated
70	as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), started in Wuhan, China, in
71	December 2019 [1, 2]. To date, the outbreak has spread rapidly around the world [1, 2], and WHO
72	has declared it a pandemic. Clinical trials have evaluated several drugs to date, with remdesivir and
73	systemic corticosteroids showing promise for moderate and severe diseases, respectively [3].
74	Several characteristic clinical findings, such as fever and dry cough with typical signs of pneumonia
75	on chest computed tomography [4-6], history of close contact with a patient or visits to endemic
76	areas [7, 8], are useful in diagnosing COVID-19. However, many patients have mild symptoms or
77	are asymptomatic, hampering accurate diagnosis based on clinical features [9-11]. Therefore, a
78	rapid diagnostic method is necessary in order to provide definitive diagnosis of COVID-19.
78 79	rapid diagnostic method is necessary in order to provide definitive diagnosis of COVID-19. Real-time reverse transcription–polymerase chain reaction (RT-PCR) is widely used for
78 79 80	rapid diagnostic method is necessary in order to provide definitive diagnosis of COVID-19. Real-time reverse transcription–polymerase chain reaction (RT-PCR) is widely used for diagnosis of COVID-19 [12, 13]. The method is very useful for testing large numbers of samples at
78 79 80 81	rapid diagnostic method is necessary in order to provide definitive diagnosis of COVID-19. Real-time reverse transcription–polymerase chain reaction (RT-PCR) is widely used for diagnosis of COVID-19 [12, 13]. The method is very useful for testing large numbers of samples at large hospitals, diagnostic companies, and local health facilities. However, a point-of-care (POC)
78 79 80 81 82	rapid diagnostic method is necessary in order to provide definitive diagnosis of COVID-19. Real-time reverse transcription–polymerase chain reaction (RT-PCR) is widely used for diagnosis of COVID-19 [12, 13]. The method is very useful for testing large numbers of samples at large hospitals, diagnostic companies, and local health facilities. However, a point-of-care (POC) test for COVID-19 is also important for management of suspected patients in less resourced settings.
78 79 80 81 82 83	rapid diagnostic method is necessary in order to provide definitive diagnosis of COVID-19. Real-time reverse transcription–polymerase chain reaction (RT-PCR) is widely used for diagnosis of COVID-19 [12, 13]. The method is very useful for testing large numbers of samples at large hospitals, diagnostic companies, and local health facilities. However, a point-of-care (POC) test for COVID-19 is also important for management of suspected patients in less resourced settings. In addition, because expansion of COVID-19 to developing countries is a major public health
78 79 80 81 82 83 83	rapid diagnostic method is necessary in order to provide definitive diagnosis of COVID-19. Real-time reverse transcription–polymerase chain reaction (RT-PCR) is widely used for diagnosis of COVID-19 [12, 13]. The method is very useful for testing large numbers of samples at large hospitals, diagnostic companies, and local health facilities. However, a point-of-care (POC) test for COVID-19 is also important for management of suspected patients in less resourced settings. In addition, because expansion of COVID-19 to developing countries is a major public health concern, there is an urgent need to develop rapid diagnostic tests for COVID-19. Real-time RT-PCR
 78 79 80 81 82 83 84 85 	rapid diagnostic method is necessary in order to provide definitive diagnosis of COVID-19. Real-time reverse transcription–polymerase chain reaction (RT-PCR) is widely used for diagnosis of COVID-19 [12, 13]. The method is very useful for testing large numbers of samples at large hospitals, diagnostic companies, and local health facilities. However, a point-of-care (POC) test for COVID-19 is also important for management of suspected patients in less resourced settings. In addition, because expansion of COVID-19 to developing countries is a major public health concern, there is an urgent need to develop rapid diagnostic tests for COVID-19. Real-time RT-PCR requires a special thermal cycler with precision optics that monitor fluorescence emission from

It is made available under a CC-BY-ND 4.0 International license .

87	template nucleotides under isothermal conditions with efficiency and specificity as high as those of
88	nested double PCR [14]. Due to its speed, ease of use, and cost-effectiveness, LAMP has been
89	widely used for POC testing for various infectious diseases, including COVID-19 [14-17].
90	Furthermore, the dry LAMP reagent mixture, which can be stored at 4°C, is much easier to handle
91	and more heat-stable than liquid reagents. Therefore, the dry LAMP method would very useful for
92	diagnosis of tropical infectious diseases in regions including Africa [18], which is expected to be the
93	next epicenter of COVID-19. The aim of this study was to evaluate the performance of the LAMP
94	method using dry reagents for rapid diagnosis of COVID-19 infection. Although several studies
95	have already been published on the use of LAMP to detect SARS-CoV-2 [19-21], this is the first
96	study to evaluate the performance of dry LAMP reagents for this purpose.

It is made available under a CC-BY-ND 4.0 International license .

98 Materials and methods

99

100 Viruses and RNA for initial validation analysis

101 A total of 22 respiratory pathogens were used for the initial validation analysis of specificity of the

102 primers in this study. Twenty-two viral genomes are listed in Table 1. The Middle East respiratory

103 syndrome coronavirus (MERS-CoV) EMC strain was kindly provided from Dr. Ron A. M. Fouchier,

104 Erasmus Medical Center, Rotterdam, the Netherlands. The SARS-CoV Frankfurt 1 strain was

105 kindly provided from J. Ziebuhr, University of Würzburg, Germany. The clinical isolates of Human

106 coronaviruses (HCoV)-HKU1, OC43, NL63, and 229E were described by previous study [22-24].

107 In vitro transcribed RNA (GenBank accession number MN908947), synthesized using ScriptMax

108 Thermo T7 Transcription Kit (TOYOBO, Osaka, Japan), was used to determine the detection limit

109 of the Loopamp SARS-CoV-2 Detection kit (Eiken Chemical, Tokyo, Japan).

110

111 Clinical specimens

112 From March 7 to April 30, 2020, nasopharyngeal swabs were collected from patients suspected to

113 have COVID-19 at a university hospital in Japan. Swab samples were collected using a flocked

sterile plastic swab applicator and placed in 3 mL of BD universal viral transport medium (Becton,

115 Dickinson and Company, Franklin Lakes, NJ, USA). RNA was extracted from the swab samples

116 immediately. This study was approved by the institutional review board of Fujita Health University

117 (No. HM19-493). Written informed consent was obtained from each patient.

It is made available under a CC-BY-ND 4.0 International license .

1	1	8
_	_	~

119 **RNA extraction**

- 120 Viral RNA was extracted from 140 µL of BD universal viral transport medium in which a
- 121 nasaopharyngeal swab was immersed. RNA extraction was performed using the QIAamp Viral
- 122 RNA mini kit (QIAGEN, Chatsworth, CA, USA). After extraction, RNA was eluted in 60 µL of
- 123 buffer AVE and stored at -80° C.
- 124

125 Real-time RT-PCR

126Real-time RT-PCR assays for detecting SARS-CoV-2 were performed using TaqMan Fast Virus 1271-Step Master Mix (Thermo Fisher Scientific, Waltham, MA, USA). Primers and probes were as 128follows: NIID_2019-nCOV_N_F2, 5'-AAATTTTGGGGGACCAGGAAC-3'; NIID_2019-nCOV_N_R2, 5'- TGGCAGCTGTGTAGGTCAAC-3'; NIID_2019-nCOV_N_P2; 5'-129130 FAM ATGTCGCGCATTGGCATGGA BHQ-3' [25]. Single-well denaturation, reverse transcription, and amplification steps were performed on a QuantStudio 1 Real-Time PCR System (Thermo 131132Fisher Scientific, Waltham, MA, USA) in the standard mode. Primer and probe concentrations were 133follows: NIID 2019-nCOV N F2, 500 nM; NIID 2019-nCOV N R2, 700 nM: as NIID_2019-nCOV_N_P2, 200 nM. PCR conditions were as follows: RT at 50 °C for 5 min; 134enzyme activation at 95 °C for 20 sec; and 45 cycles of denaturation at 95 °C for 15 sec and primer 135136annealing/extension/fluorescence emission at 60°C for 60 sec. The real-time RT-PCR reaction 137mixture (20 µL total volume) contained 5.0 µL of 4× Fast Virus Master Mix, 1.0 µL of

It is made available under a CC-BY-ND 4.0 International license .

138 primer–probe pre-mix, 5.0 µL of template RNA and nuclease-free water.

139

140 Reverse Transcription–LAMP

141	Reverse transcription (RT)-LAMP was carried out using the Loopamp SARS-CoV-2 Detection kit
142	(Eiken Chemical). Because the entire mixture except the primers is dried and immobilized inside
143	the tube lid, 10 microliters of purified RNA and 15 microliters of SARS-CoV-2 specific primer sets
144	were added to the bottom of the tube, and then the tube was inverted several times to resuspend the
145	enzyme and buffer. The full reaction mixture was collected at the bottom of the tube by a quick
146	spin-down. The mixture was incubated in a real-time turbidimeter (LA-200; Eiken Chemical) for 35
147	min at 62.5°C. For visual evaluation of fluorescence, the reaction tube was illuminated with
148	ultraviolet light using an ultraviolet illumination system (WSE-5300; ATTO, Tokyo, Japan) and and
149	also observed by the naked eye.

It is made available under a CC-BY-ND 4.0 International license .

151 **Results**

152

153 Specificity and sensitivity of LAMP methods.

154To determine the specificity of the Loopamp SARS-CoV-2 Detection kit, we tested 22 viral 155genomes including SARS coronavirus, Middle East Respiratory Syndrome (MERS) coronavirus, other human coronaviruses, influenza viruses, and respiratory syncytial viruses associated with 156157respiratory infections (Table 1). No LAMP product was detected in reactions performed with RNA from these pathogens. These results were confirmed by a turbidity assay and agarose gel 158electrophoresis analysis (data not shown). To determine the sensitivity of the Loopamp 159160 SARS-CoV-2 Detection kit, in vitro transcribed RNAs were serially diluted in 10 mM Tris buffer 161containing 0.1 mM EDTA and 50 ng/mL of carrier RNA were used to define the detection limit. The 162sensitivity of this assay, determined by either the turbidity assay or colorimetric change of the 163 reaction mixtures evaluated by the naked eye, was 10 copies/reaction (Fig. 1).

164

165 **Evaluation of clinical applications**

To evaluate the performance of the Loopamp SARS-CoV-2 Detection kit as a POC test, we analyzed 24 nasopharyngeal specimens collected from patients suspected of having COVID-19, including three asymptomatic individuals who came into close contact with COVID-19 patients (Table 2). Nineteen (79.2%) of the 24 samples were positive for SARS-CoV-2 RNA by real-time RT-PCR analysis. Using the Loopamp SARS-CoV-2 Detection kit, SARS-CoV-2 RNA was detected

It is made available under a CC-BY-ND 4.0 International license .

- in 15 (62.5%) of the 24 samples. The four false-negative samples contained low copies of viral
- 172 RNA (2.6, 2.3, 2.2, and 0.5 copies/reaction) and were collected during the convalescent phase of
- 173 illness (days 7 to 20). Thus, the sensitivity, specificity, positive predictive value, and negative
- predictive value of the Loopamp SARS-CoV-2 Detection kit were 78.9%, 100%, 100%, and 55.6%,
- 175 respectively.
- 176

It is made available under a CC-BY-ND 4.0 International license .

177 **Discussion**

179	Ease of use, speed, and low cost of amplifying target nucleotides is a significant advantage of the
180	LAMP assay as a POC test. Accordingly, several investigators have developed SARS-CoV-2 LAMP
181	assays [16, 19-21, 26]. To further leverage the advantages of the LAMP method, several
182	improvements have been reported, including colorimetric detection using the naked eye [20] or
183	fluorescent detector [26] and direct detection of target sequence without RNA extraction. These
184	improvements shorten and simplify the workflow of the LAMP method [20], and enable
185	high-throughput analysis. Using the LAMP method with dry reagents allows the use of this assay in
186	developing countries, as the reagents can be stored in refrigerators that overcomes the requirement
187	for strict cold-chain transportation and storage of the reagents. Therefore, in this study, we
188	investigated the performance of the SARS-CoV-2 dry LAMP method.
188 189	investigated the performance of the SARS-CoV-2 dry LAMP method. No amplification was observed with other viral genomes (including SARS coronavirus,
188 189 190	 investigated the performance of the SARS-CoV-2 dry LAMP method. No amplification was observed with other viral genomes (including SARS coronavirus, MARS coronavirus, and other human coronaviruses associated with respiratory infections) using
188 189 190 191	 investigated the performance of the SARS-CoV-2 dry LAMP method. No amplification was observed with other viral genomes (including SARS coronavirus, MARS coronavirus, and other human coronaviruses associated with respiratory infections) using the SARS-CoV-2 dry LAMP method (Table 1), indicating that this LAMP assay can specifically
188 189 190 191 192	 investigated the performance of the SARS-CoV-2 dry LAMP method. No amplification was observed with other viral genomes (including SARS coronavirus, MARS coronavirus, and other human coronaviruses associated with respiratory infections) using the SARS-CoV-2 dry LAMP method (Table 1), indicating that this LAMP assay can specifically amplify SARS-CoV-2. In addition, the detection limit of the kit, based on the turbidity assay and
188 189 190 191 192 193	 investigated the performance of the SARS-CoV-2 dry LAMP method. No amplification was observed with other viral genomes (including SARS coronavirus, MARS coronavirus, and other human coronaviruses associated with respiratory infections) using the SARS-CoV-2 dry LAMP method (Table 1), indicating that this LAMP assay can specifically amplify SARS-CoV-2. In addition, the detection limit of the kit, based on the turbidity assay and colorimetric change determined by the naked eye, was 10 copies/reaction, almost the same or
 188 189 190 191 192 193 194 	 investigated the performance of the SARS-CoV-2 dry LAMP method. No amplification was observed with other viral genomes (including SARS coronavirus, MARS coronavirus, and other human coronaviruses associated with respiratory infections) using the SARS-CoV-2 dry LAMP method (Table 1), indicating that this LAMP assay can specifically amplify SARS-CoV-2. In addition, the detection limit of the kit, based on the turbidity assay and colorimetric change determined by the naked eye, was 10 copies/reaction, almost the same or slightly higher than the previously reported SARS-CoV-2 LAMP assays [26]. These initial
 188 189 190 191 192 193 194 195 	investigated the performance of the SARS-CoV-2 dry LAMP method. No amplification was observed with other viral genomes (including SARS coronavirus, MARS coronavirus, and other human coronaviruses associated with respiratory infections) using the SARS-CoV-2 dry LAMP method (Table 1), indicating that this LAMP assay can specifically amplify SARS-CoV-2. In addition, the detection limit of the kit, based on the turbidity assay and colorimetric change determined by the naked eye, was 10 copies/reaction, almost the same or slightly higher than the previously reported SARS-CoV-2 LAMP assays [26]. These initial validation analysis demonstrated that the SARS-CoV-2 dry LAMP method is highly specific and

It is made available under a CC-BY-ND 4.0 International license .

197 without RNA extraction [20], in line with our previous studies for detection of herpes simplex virus

198 [27] and human herpesvirus-6 [28]. Therefore, to further improve the LAMP method as a POC test,

200In order to evaluate the performance of SARS-CoV-2 dry LAMP for analyzing clinical 201samples, we analyzed 24 nasopharyngeal swab specimens collected from patients suspected of 202having COVID-19. The sensitivity and specificity of this assay was sufficient for practical purposes. 203In 24 nasopharyngeal swab specimens, there are only 5 SARS-CoV-2 RNA negative samples. While 204there were 4 false-negative test results, as shown in Table 2, they represented specimens with the 205lowest copy numbers. In particular, two of the four false-negative samples were collected on days 20618 and 20 to confirm the absence of viral genome prior to hospital discharge. Given that all samples 207with more than 4.4 copies/reaction were detected by both turbidity assay and colorimetric changes, 208we believe that this SARS-CoV-2 dry LAMP method is reliable for clinical use in diagnosing 209COVID-19.

In summary, this study demonstrated that the SARS-CoV-2 dry LAMP method is a reliable method for rapid diagnosis of COVID-19. The dry LAMP method overcomes the requirement for strict cold-chain transportation and storage of reagents. Therefore, this method is expected to be a useful POC test in developing countries where COVID-19 is spreading.

214

215 Acknowledgments

216

We gratefully acknowledge Eiken Chemical for their contributions to this work.

a direct detection method should be developed.

It is made available under a CC-BY-ND 4.0 International license .

217

218 Grant support

- 219 This work was supported by the Japan Agency for Medical Research and Development
- 220 (nos. 19fk0108030j0001, JP19fk0108104, JP19fk0108110, JP19fk0108150, 20fk0108117j0001, and
- 221 20fk0108117j0101). This study was also supported by a Health Labour Sciences Research Grant
- 222 (19HA1003).

It is made available under a CC-BY-ND 4.0 International license .

223 Figure Legend

224

225	Figure	1. S	ensitivity	of	the	SARS-0	CoV-2	dry	LAMP	assay,	determined	using	serially	ŗ
			•					•		• • •			•	

- diluted *in vitro* transcribed RNA. (a) Naked-eye detection at the end of assay (35 min).
- Green indicates a positive reaction, and orange indicates a negative reaction. (b) Ultraviolet
- light detection at the end of the assay (35 min). Light gray indicates a positive reaction, and
- 229 dark gray indicates a negative reaction. (C) Real-time turbidity assay.

It is made available under a CC-BY-ND 4.0 International license .

231 **References**

- 232 1. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus
- associated with human respiratory disease in China. Nature. 2020;579(7798):265-9. Epub
- 234 2020/02/06. doi: 10.1038/s41586-020-2008-3. PubMed PMID: 32015508; PubMed Central
- 235 PMCID: PMCPMC7094943.
- 236 2. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak
- associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-3.
- 238 Epub 2020/02/06. doi: 10.1038/s41586-020-2012-7. PubMed PMID: 32015507; PubMed
- 239 Central PMCID: PMCPMC7095418.

240 3. Bimonte S, Crispo A, Amore A, Celentano E, Cuomo A, Cascella M. Potential

- 241 Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical
- Research. In Vivo. 2020;34(3 Suppl):1597-602. Epub 2020/06/07. doi:
 10.21873/invivo.11949. PubMed PMID: 32503817.

Liu M, Zeng W, Wen Y, Zheng Y, Lv F, Xiao K. COVID-19 pneumonia: CT findings
 of 122 patients and differentiation from influenza pneumonia. Eur Radiol. 2020. Epub
 2020/05/14. doi: 10.1007/s00330-020-06928-0. PubMed PMID: 32399710; PubMed Central
 PMCID: PMCPMC7216854.

5. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81

It is made available under a CC-BY-ND 4.0 International license .

patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis.

- 250 2020;20(4):425-34. Epub 2020/02/28. doi: 10.1016/S1473-3099(20)30086-4. PubMed PMID:
- 251 32105637; PubMed Central PMCID: PMCPMC7159053.
- 252 6. Wang H, Wei R, Rao G, Zhu J, Song B. Characteristic CT findings distinguishing
- 253 2019 novel coronavirus disease (COVID-19) from influenza pneumonia. Eur Radiol.
- 254 2020;30(9):4910-7. Epub 2020/04/24. doi: 10.1007/s00330-020-06880-z. PubMed PMID:
- 255 32323011; PubMed Central PMCID: PMCPMC7175830.
- 256 7. Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z, et al. Epidemiology and transmission of
- 257 COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective
- 258 cohort study. Lancet Infect Dis. 2020;20(8):911-9. Epub 2020/05/01. doi:
 259 10.1016/S1473-3099(20)30287-5. PubMed PMID: 32353347; PubMed Central PMCID:
 260 PMCPMC7185944.
- 8. Ding J, Tuan WJ, Temte JL. Managing Close Contacts of COVID-19 Confirmed
 Cases in Metropolitan Areas in China. J Public Health Manag Pract. 2020;26(4):345-8. Epub
 2020/04/26. doi: 10.1097/PHH.000000000001189. PubMed PMID: 32332481; PubMed
 Central PMCID: PMCPMC7252620.
- 265 9. Liu YC, Liao CH, Chang CF, Chou CC, Lin YR. A Locally Transmitted Case of
 266 SARS-CoV-2 Infection in Taiwan. N Engl J Med. 2020;382(11):1070-2. Epub 2020/02/13.

It is made available under a CC-BY-ND 4.0 International license .

267 doi: 10.1056/NEJMc2001573. PubMed PMID: 32050059; PubMed Central PMCID:
268 PMCPMC7121202.

- 269 10. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al.
- 270 Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. N Engl J
- 271 Med. 2020;382(10):970-1. Epub 2020/02/01. doi: 10.1056/NEJMc2001468. PubMed PMID:
- 272 32003551; PubMed Central PMCID: PMCPMC7120970.
- 273 11. Yu P, Zhu J, Zhang Z, Han Y. A Familial Cluster of Infection Associated With the
- 274 2019 Novel Coronavirus Indicating Possible Person-to-Person Transmission During the
- 275Incubation Period. J Infect Dis. 2020;221(11):1757-61. Epub 2020/02/19. doi: 27610.1093/infdis/jiaa077. PubMed PMID: 32067043; PubMed Central PMCID: 277PMCPMC7107453.
- 27812. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in 279Different Types of Clinical Specimens. JAMA. 2020. Epub 2020/03/12. doi: PubMed 28010.1001/jama.2020.3786. PubMed PMID: 32159775; Central PMCID: PMCPMC7066521. 281
- Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection
 of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3).
 Epub 2020/01/30. doi: 10.2807/1560-7917.ES.2020.25.3.2000045. PubMed PMID:

It is made available under a CC-BY-ND 4.0 International license .

285 31992387; PubMed Central PMCID: PMCPMC6988269.

286	14. Notomi T, Mori Y, Tomita N, Kanda H. Loop-mediated isothermal amplification
287	(LAMP): principle, features, and future prospects. J Microbiol. 2015;53(1):1-5. Epub
288	2015/01/06. doi: 10.1007/s12275-015-4656-9. PubMed PMID: 25557475.
289	15. Iwamoto T, Sonobe T, Hayashi K. Loop-mediated isothermal amplification for direct
290	detection of Mycobacterium tuberculosis complex, M. avium, and M. intracellulare in sputum
291	samples. J Clin Microbiol. 2003;41(6):2616-22. Epub 2003/06/07. doi:
292	10.1128/jcm.41.6.2616-2622.2003. PubMed PMID: 12791888; PubMed Central PMCID:
293	PMCPMC156570.
294	16. Nzelu CO, Caceres AG, Guerrero-Quincho S, Tineo-Villafuerte E, Rodriquez-Delfin
295	L, Mimori T, et al. A rapid molecular diagnosis of cutaneous leishmaniasis by colorimetric
296	malachite green-loop-mediated isothermal amplification (LAMP) combined with an FTA card
297	as a direct sampling tool. Acta Trop. 2016;153:116-9. Epub 2015/10/31. doi:
298	10.1016/j.actatropica.2015.10.013. PubMed PMID: 26516109.
299	17. Higashimoto Y, Kawamura Y, Kuboshiki A, Hattori F, Miura H, Nishimura N, et al.

- 300 Reliability of direct varicella zoster virus loop-mediated isothermal amplification method for
- rapid diagnosis of breakthrough varicella. J Clin Virol. 2019;119:53-8. Epub 2019/09/07. doi:
- 302 10.1016/j.jcv.2019.07.009. PubMed PMID: 31491710.

It is made available under a CC-BY-ND 4.0 International license .

303	18. Hayashida K, Kajino K, Hachaambwa L, Namangala B, Sugimoto C. Direct blood
304	dry LAMP: a rapid, stable, and easy diagnostic tool for Human African Trypanosomiasis.
305	PLoS Negl Trop Dis. 2015;9(3):e0003578. Epub 2015/03/15. doi:
306	10.1371/journal.pntd.0003578. PubMed PMID: 25769046; PubMed Central PMCID:
307	PMCPMC4358998.
308	19. Dao Thi VL, Herbst K, Boerner K, Meurer M, Kremer LP, Kirrmaier D, et al. A
309	colorimetric RT-LAMP assay and LAMP-sequencing for detecting SARS-CoV-2 RNA in
310	clinical samples. Sci Transl Med. 2020;12(556). Epub 2020/07/29. doi:
311	10.1126/scitranslmed.abc7075. PubMed PMID: 32719001.
312	20. Huang WE, Lim B, Hsu CC, Xiong D, Wu W, Yu Y, et al. RT-LAMP for rapid
313	diagnosis of coronavirus SARS-CoV-2. Microb Biotechnol. 2020;13(4):950-61. Epub
314	2020/04/26. doi: 10.1111/1751-7915.13586. PubMed PMID: 32333644; PubMed Central
315	PMCID: PMCPMC7264870.
316	21. Yu L, Wu S, Hao X, Dong X, Mao L, Pelechano V, et al. Rapid Detection of
317	COVID-19 Coronavirus Using a Reverse Transcriptional Loop-Mediated Isothermal
318	Amplification (RT-LAMP) Diagnostic Platform. Clin Chem. 2020;66(7):975-7. Epub

- 319 2020/04/22. doi: 10.1093/clinchem/hvaa102. PubMed PMID: 32315390; PubMed Central
- 320 PMCID: PMCPMC7188121.

It is made available under a CC-BY-ND 4.0 International license .

.

321	22. Shirato K, Kawase M, Matsuyama S. Wild-type human coronaviruses prefer
322	cell-surface TMPRSS2 to endosomal cathepsins for cell entry. Virology. 2018;517:9-15. Epub
323	2017/12/09. doi: 10.1016/j.virol.2017.11.012. PubMed PMID: 29217279; PubMed Central
324	PMCID: PMCPMC7112029.
325	23. Kazuya S, Nao N, Matsuyama S, Kageyama T. Ultra-Rapid Real-Time RT-PCR
326	Method for Detecting Middle East Respiratory Syndrome Coronavirus Using a Mobile PCR

. . . .

- 327 Device, PCR1100. Jpn J Infect Dis. 2020;73(3):181-6. Epub 2019/12/26. doi:
- 32810.7883/yoken.JJID.2019.400. PubMed PMID: 31875608.
- 24. 329 Shirato K, Kawase M, Watanabe O, Hirokawa C, Matsuyama S, Nishimura H, et al.
- 330 Differences in neutralizing antigenicity between laboratory and clinical isolates of
- 331 HCoV-229E isolated in Japan in 2004-2008 depend on the S1 region sequence of the spike
- 332protein. J Gen Virol. 2012;93(Pt 9):1908-17. Epub 2012/06/08. doi: 10.1099/vir.0.043117-0.
- 333 PubMed PMID: 22673931.

a1 ·

- 25. 334Shirato K, Nao N, Katano H, Takayama I, Saito S, Kato F, et al. Development of
- Genetic Diagnostic Methods for Detection for Novel Coronavirus 2019(nCoV-2019) in Japan. 335
- 336 Jpn J Infect Dis. 2020;73(4):304-7. Epub 2020/02/20. doi: 10.7883/yoken.JJID.2020.061.
- 337 PubMed PMID: 32074516.
- Yan C, Cui J, Huang L, Du B, Chen L, Xue G, et al. Rapid and visual detection of 338 26.

It is made available under a CC-BY-ND 4.0 International license .

2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated isothermal
amplification assay. Clin Microbiol Infect. 2020;26(6):773-9. Epub 2020/04/11. doi:
10.1016/j.cmi.2020.04.001. PubMed PMID: 32276116; PubMed Central PMCID:
PMCPMC7144850.

27. Enomoto Y, Yoshikawa T, Ihira M, Akimoto S, Miyake F, Usui C, et al. Rapid 343 diagnosis of herpes simplex virus infection by a loop-mediated isothermal amplification 344J 345method. Clin Microbiol. 2005;43(2):951-5. Epub 2005/02/08. doi: 346 10.1128/JCM.43.2.951-955.2005. PubMed PMID: 15695716; PubMed Central PMCID: PMCPMC548035. 347

348 28. Ihira M, Akimoto S, Miyake F, Fujita A, Sugata K, Suga S, et al. Direct detection of

human herpesvirus 6 DNA in serum by the loop-mediated isothermal amplification method. J

Clin Virol. 2007;39(1):22-6. Epub 2007/03/23. doi: 10.1016/j.jcv.2007.02.001. PubMed
PMID: 17376739.

Figure 1.



Virus	Name of isolate	Amount (copies / reaction)
Coronaviruses		
SARS-CoV	Frankfurt-1	$4.00 imes 10^7$
MERS-CoV	EMC	1.00×10^5
Human coronaviruses (HCoV)		
HCoV-HKU1	Tokyo/SGH-15/2014	$6.00 imes 10^6$
	Tokyo/SGH-18/2016	$1.00 imes 10^6$
HCoV-OC43	VR-1558	$4.00 imes 10^8$
	Tokyo/SGH-36/2014	3.00×10^{6}
	Tokyo/SGH-61/2014	$1.00 imes 10^7$
	Tokyo/SGH-6/2015	$4.00 imes 10^6$
	Tokyo/SGH-65/2016	$1.00 imes 10^7$
HCoV-NL63	Amsterdam I	$8.00 imes 10^7$
	Tokyo/SGH-15/2017	$1.00 imes 10^5$
	Tokyo/SGH-24/2018	$4.00 imes 10^4$
HCoV-229E	VR-740	$7.00 imes 10^7$
	Sendai-H/1121/04	$1.00 imes 10^6$
	Niigata/01/08	$1.00 imes 10^5$
Influenza virus		
А	A/Texas/50/2012(H3N2)	$1.18 imes 10^6$
	A/Narita/1/2009(H1N1)	2.94×10^{6}
В	B/Massachusetts/2/2012	4.44×10^{6}
	B/Texas/2/2013	1.46×10^{7}
	B/Brisbane/60/2008	2.00×10^5
Respiratory syncytial virus (RSV)		
	A2	1.00×10^{6}
	B1	1.00×10^{6}

Table 1. Specificity of dry loop-mediated isothermal amplification assay forSARS-CoV-2.

Casa	Someling day*	Real-time RT-PCR		
Case	Sampling day*	(copies/ reaction)	LAMP	
1	unknown**	212732.5	+	
2	unknown**	94749.3	+	
3	7	22910.9	+	
4	5	3796.9	+	
5	11	1544.6	+	
6	10	946.9	+	
7	8	413.9	+	
8	8	280.8	+	
9	9	146.0	+	
10	unknown**	68.7	+	
11	12	49.8	+	
12	12	48.9	+	
13	7	14.2	+	
14	8	13.2	+	
15	19	4.4	+	
16	7	2.6	-	
17	18	2.3	-	
18	10	2.2	-	
19	20	0.5	-	
20	14	0.0	-	
21	8	0.0	-	
22	12	0.0	-	
23	10	0.0	-	
24	12	0.0	-	

Table 2. Comparison of real-time RT-PCR and dry loop-mediated isothermalamplification assay results of SARS-CoV-2 using clinical specimens.

* Onset of disease was defined as day 1.

** Sampling day was unknown because the patient was asymptomatic.